Home / Health / Pfizer says its booster shot is 95.6% effective against symptomatic Covid

Pfizer says its booster shot is 95.6% effective against symptomatic Covid

Regulators have wrestled with how widely to use boosters as the fast-spreading delta variant drives infection rates up

Premium

The trial results show that “booster vaccinations could play an important role in sustaining pandemic containment and a return to normalcy,” BioNTech CEO Ugur Sahin said.

Naomi Kresge | Bloomberg

2 min read Last Updated : Oct 21 2021 | 4:59 PM IST

Pfizer Inc. and BioNTech SE said a booster shot of their Covid-19 vaccine restored full protection in a large study, results that are likely to bolster the argument for giving a third dose more widely.

A booster was 95.6% effective against symptomatic Covid in the study, which followed 10,000 people aged 16 and older, the companies said on Thursday.

Pfizer shares were 0.9% higher in premarket U.S. trading, with BioNTech gaining 1.3% in Frankfurt.

“We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,” Pfizer Chief Executive Officer Albert Bourla said in a

Topics : Pfizer Coronavirus Vaccine

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in